Annovis Bio Inc. Secures Comprehensive Patent Coverage for Buntanetap, Enhancing Treatment Potential for Neurodegenerative Diseases

Annovis Bio Inc. (NYSE: ANVS), a late-stage clinical company focused on neurodegenerative diseases, has announced a significant expansion in its intellectual property rights. The company now holds full patent coverage for both the original and a new crystalline form of buntanetap, a compound under investigation for its potential to treat conditions such as Alzheimer's disease (AD) and Parkinson's disease (PD). This patent protection is comprehensive, encompassing the composition of matter, mechanism of action, and use across multiple indications, and is secured through 2046.

The new crystalline form of buntanetap has demonstrated improved stability, with bioequivalence confirmed in both animal and human studies. These findings were recently presented at the 2025 Alzheimer’s Association International Conference, underscoring the compound's potential as a groundbreaking treatment option. The stability and bioequivalence of the new form are critical factors that could enhance its efficacy and safety profile, making it a more viable option for patients suffering from neurodegenerative diseases.

This development is particularly significant given the growing need for effective treatments for neurodegenerative diseases, which affect millions of people worldwide. The expansion of Annovis Bio's patent portfolio not only strengthens the company's position in the biotech industry but also represents a hopeful advancement for patients and families affected by these debilitating conditions. For more details on this announcement, visit https://ibn.fm/gtiNb.

The implications of this patent coverage extend beyond the immediate benefits to Annovis Bio. It sets a precedent for the protection and development of innovative therapies in the neurodegenerative disease space, encouraging further research and investment in this critical area of medicine. The company's commitment to improving patient outcomes and quality of life through innovative therapies is evident in this strategic expansion of its intellectual property rights.